Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03802123 · ClinicalTrials.gov registry record · Phase 2
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
A Phase 2 study, sponsored by ImaginAb.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT03802123 is a Phase 2 study that has completed, run by ImaginAb. The registered enrollment target is 52 participants.
The verdict
NCT03802123, a Phase 2 study, has completed, sponsored by ImaginAb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by immunohistochemical staining in patients with selected advanced and metastatic solid malignancies who are scheduled to receive standard of care immunotherapy. The study will also evaluate uptake of ⁸⁹Zr-Df-IAB22M2C by PET/CT in patients at baseline and on immunotherapy.
Interventions
- DRUG ⁸⁹Zr-Df-IAB22M2C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-12-18 |
| Est. Completion | 2022-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03802123
The ClinicalTrials.gov registry entry for NCT03802123 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImaginAb, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ⁸⁹Zr-Df-IAB22M2C is the first listed.
NCT03802123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03802123 about?
NCT03802123 is a clinical study titled "⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors". The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by immunohistochemical staining in patients with selected advanced and metastatic solid malignancies who are scheduled ...
What is the current status of trial NCT03802123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2018-12-18. Estimated completion is 2022-07-18.
What interventions are being tested in trial NCT03802123?
The interventions under investigation include: ⁸⁹Zr-Df-IAB22M2C (DRUG).
Who is sponsoring clinical trial NCT03802123?
This trial is sponsored by ImaginAb, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.